Dean L. Mann*, Kelsey Pitts*, Etse Gebru, Kim Hankey*,  Kenichiro Hasumi**

* University of Maryland School of Medicine, Baltimore MD, USA

**Hasumi International Research Foundation, Tokyo, Japan


Immunologic approaches to cancer treatment have shown promising results. A protocol combining standard of care radiation with intra-tumor injection of autologous dendritic cells (antigen presenting cells) together with infusion of cytokine activated T cells was developed to treat patients with advanced and /or recurrent solid tumors.

Radiation contributes to the development of this anti-cancer vaccine by inducing death of tumor cells with release of potential antigenic products, expression of heat-shock proteins and amphoterin, and release of pro-inflammatory cytokines.

In this milieu, injected DC can acquire tumor-associated molecules under conditions favorable for antigen presentation and induction of adaptive immune response. The antigen-armed DCs migrate to regional lymph nodes where adaptive immune responses (antibodies, cytotoxic T cells) are generated. We tested serum and cells obtained from patients before after treatment for the development for antibody responses to known tumor associated antigens and cellular immune responses to cell lines established from autologous tumors.

In post treatment specimens, specific cellular responses to autologous tumor cell lines were documented as was an increase in serum antibody titers to a known tumor associated antigen. The increased levels of antibody reactivity were concurrent with radiographic evidence of tumor resolution at the treated sites.

These results document the generation of cellular and antibody immune responses in patients with advanced solid tumors treated on the Hasumi HITV protocol.


Prof. Dean L. Mann, MD

University of Maryland School of Medicine, Baltimore MD, USA


Dean L Mann MD is professor and head of the Division of Immunogenetics in the Department of Pathology at the University of Maryland School of Medicine. He also has a joint appointment of the Department of Microbiology and Immunology and is a member of the Program in Oncology in the Marlene and Stuart Greenebaum Cancer Center.


Dr. Mann received his medical degree at St. Louis University School of Medicine and completed his residency in Internal Medicine at the University’s group of Hospitals. He was awarded a post doctoral fellowship in the National Cancer Institute at the National Institute of Health. After completion, he served for some 28 years as Senior Investigator and Section Head of various Branches and Laboratories in the NCI. Dr. Mann accepted his current position at the University of Maryland approximately 20 years ago.


Dr. Mann is recognized nationally and internationally for his research in Human Immunogenetics. He and his colleagues were among the first to isolate HLA molecules in soluble form, results that led to the elucidation of their molecular composition, crystal structure and function as primary regulators of the immune response. His pioneering work in this area resulted in extensive collaborations with basic and clinical scientists in the US and worldwide leading to the first reports of   associations of specific alleles of genes encoding HLA class I and Class II molecules with wide number of  autoimmune diseases and contributed to the relative rates of  disease progression in HIV infected individuals.


Recognition of his expertise in human immunology led to collaborations with scientists in other areas including virology and cancer. Examples of the former include demonstration that human cord blood lymphocytes were capable of being infected with primary sources of HTLV I and that this human retro virus played an indirect role in CLL leukemogenesis in an infected individual. Extensive collaborations were established with members of Dr Robert Gallo’s group at the NCI in the early studies of HIV.


Since coming to the University of Maryland, Dr. Mann has continued his research efforts in the above areas focusing on auto immune disease and Cancer, the latter in the area of cancer immunology and Immunotherapy. He and members of the Department of Otorhinolaryngology developed an FDA approved IND, an immunotherapy protocol to treat patients with advanced cancers.